Expert Opinion on the Effectiveness of Proton Pump Inhibitors Therapy in Gastroesophageal Reflux Disease in Indian Settings

Manjula S *

Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.

Krishna Kumar M

Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.

*Author to whom correspondence should be addressed.


Abstract

Objective: To gather expert opinion regarding the commonly prescribed proton pump inhibitors (PPIs) in clinical practice, with a specific focus on the use of pantoprazole as a treatment for gastroesophageal reflux disease (GERD) in Indian settings.

Methodology: The questionnaire-based survey, comprised of 19 questions, collected perspectives of experts across various regions of India regarding the usage of PPI therapy for the management of GERD in their clinical practice.

Results: The present survey included 238 participants. The majority (84%) of the clinicians recommended PPIs as the first-line therapy for gastritis. According to 85% of clinicians, there were no significant side effects associated with PPI use in GERD treatment. Most of the experts (92%) recommended pantoprazole as the most frequently prescribed PPI.  Approximately 46% of experts preferred pantoprazole 20 mg for pediatric use, while 41% preferred prescribing pantoprazole 80 mg for adults. A significant portion (63%) of clinicians suggested pantoprazole as an adjuvant therapy alongside other medications. The benefits of using pantoprazole include a quicker onset of action, safety, good tolerance, and extended acid suppression, as reported by 71%, 14%, and 13% of experts, respectively.

Conclusion: As per the expert consensus, PPI was the preferred first-line therapy for gastritis and GERD with negligible side effects. Pantoprazole emerged as the most favorable PPI for GERD treatment and was also regarded as a valuable adjuvant therapy when combined with other medications. Experts have shown a preference for prescribing 20 mg and 80 mg doses of pantoprazole for children and adults, respectively. With its rapid onset of action, safety profile, excellent tolerability, and sustained acid suppression, pantoprazole presented significant advantages, making it a valuable therapeutic option for GERD treatment.

Keywords: Proton pump inhibitors, pantoprazole, gastroesophageal reflux disease, Indian setting, survey


How to Cite

Manjula S, & Krishna Kumar M. (2024). Expert Opinion on the Effectiveness of Proton Pump Inhibitors Therapy in Gastroesophageal Reflux Disease in Indian Settings. Asian Journal of Research and Reports in Gastroenterology, 7(1), 34–41. Retrieved from https://journalajrrga.com/index.php/AJRRGA/article/view/127

Downloads

Download data is not yet available.

References

Boulton KHA, Dettmar PW. A narrative review of the prevalence of gastroesophageal reflux disease (GERD). Annals of Esophagus. 2022;5:7.

Nirwan JS, Hasan SS, Babar ZUD, Conway BR, Ghori MU. Global prevalence and risk factors of Gastro-oesophageal Reflux Disease (GORD): Systematic review with meta-analysis. Sci Rep. 2020; 10(1):5814.

Zhang D, Liu S, Li Z, Wang R. Global, regional and national burden of gastroesophageal reflux disease, 1990–2019: update from the GBD 2019 study. Annals of Medicine. 2022;54(1):1372–84.

Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018;67(3):430–40.

Bhatia S, Pareek KK, Kumar A, Upadhyay R, Tiwaskar M, Jain A, et al. API-ISG Consensus guidelines for management of gastrooesophageal reflux disease. J Assoc Physicians India. 2020;68(10):69–80.

Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40(2): 209–19.

Khan MA, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. Gastroenterol Hepatol (N Y). 2018;14(3):169–75.

Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. Gut Liver. 2018;12(1):7–16.

Katz PO, Dunbar K, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical guideline: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27–56.

Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010; 3:11–6.

Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag. 2007;3(2):231–43.

Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991;35(3):490–6.

Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull. 1995;18(8):1053–6.

Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;17(6):751–64.

Gisbert JP, Pajares JM. Esomeprazole-based therapy in helicobacter pylori eradication: A meta-analysis. Dig Liver Dis. 2004;36(4):253–9.

Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16(1):89–99.

Wang X, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion. 2006;73(2–3):178–86.

Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002; 4:CD002296.

de la Coba Ortiz C, Argüelles Arias F, Martín de Argila de Prados C, Júdez Gutiérrez J, Linares Rodríguez A, Ortega Alonso A, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva. Rev Esp Enferm Dig. 2016;108(4):207–24.

Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15(7):927–35.

Dabrowski A, Štabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR. Prz Gastroenterol. 2018;13(1):6–15.

Pilotto A, Franceschi M, Leandro G, Scarcelli C, D’Ambrosio LP, Paris F, et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007;13(33):4467–72.

Devault KR. Pantoprazole: A proton pump inhibitor with oral and intravenous formulations. Expert Rev Gastroenterol Hepatol. 2007;1(2):197–205.

Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, et al. Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. J Gastroenterol Hepatol. 2006;21(4):716–21.

Wang J, Yang K, Ma B, Tian J, Liu Y, Bai Z, et al. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. Can J Gastroenterol. 2009;23(4):287–99.

V T, Pr B, Vm T, D G, Ef S, Gm C, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42(4):384–91.

Madrazo-de la Garza A, Dibildox M, Vargas A, Delgado J, Gonzalez J, Yañez P. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr. 2003;36(2):261–5.

van Rensburg CJ, Cheer S. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. Clin Med Insights Gastroenterol. 2012; 5:51–60.

Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol. 1999;11(11):1277–82.

Sivri B, Simsek ilkay, Hulagu S, Kadayifci A, Tozun N, Akarsu M, et al. The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. Current Medical Research and Opinion. 2004;20(8):1301–7.

Remes-Troche JM, Sobrino-Cossío S, Soto-Pérez JC, Teramoto-Matsubara O, Morales-Arámbula M, Orozco-Gamiz A, et al. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): A prospective, multicenter, post-marketing observational study. Clin Drug Investig. 2014;34(2): 83–93.

Van Rensburg CJ, Honiball, Van Zyl JH, Grundling HDK, Eloff, Spies, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-A 2-year follow-up. Alimentary Pharmacology & Therapeutics. 1999;13(8):1023–8.